New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies

New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies

MMP intervention strategies have met with limited clinical success due to severe toxicities. In particular, treatment with broad-spectrum MMP-inhibitors (MMPIs) caused musculoskeletal pain and inflammation. Selectivity may be essential for realizing the clinical potential of MMPIs. Here we review di...

Full description

Bibliographic Details
Main Authors: Laetitia Devy, Daniel T. Dransfield
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Biochemistry Research International
Online Access:http://dx.doi.org/10.1155/2011/191670
id doaj-06cf5881bfaf4ecfa4677a136c1db269
record_format Article
spelling doaj-06cf5881bfaf4ecfa4677a136c1db2692020-11-24T22:21:26ZengHindawi LimitedBiochemistry Research International2090-22472090-22552011-01-01201110.1155/2011/191670191670New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic AntibodiesLaetitia Devy0Daniel T. Dransfield1Merck Serono S.A., 9 Chemin des Mines, Case postale 54, 1211 Geneva 20, SwitzerlandCell Biology and Translational Research, Dyax Corp., 300 Technology Square, Cambridge, MA 02139, USAMMP intervention strategies have met with limited clinical success due to severe toxicities. In particular, treatment with broad-spectrum MMP-inhibitors (MMPIs) caused musculoskeletal pain and inflammation. Selectivity may be essential for realizing the clinical potential of MMPIs. Here we review discoveries pinpointing membrane-bound MMPs as mediators of mechanisms underlying cancer and inflammation and as possible therapeutic targets for prevention/treatment of these diseases. We discuss strategies to target these therapeutic proteases using highly selective inhibitory agents (i.e., human blocking antibodies) against individual membrane-bound MMPs.http://dx.doi.org/10.1155/2011/191670
collection DOAJ
language English
format Article
sources DOAJ
author Laetitia Devy
Daniel T. Dransfield
spellingShingle Laetitia Devy
Daniel T. Dransfield
New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies
Biochemistry Research International
author_facet Laetitia Devy
Daniel T. Dransfield
author_sort Laetitia Devy
title New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies
title_short New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies
title_full New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies
title_fullStr New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies
title_full_unstemmed New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies
title_sort new strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored mmps with therapeutic antibodies
publisher Hindawi Limited
series Biochemistry Research International
issn 2090-2247
2090-2255
publishDate 2011-01-01
description MMP intervention strategies have met with limited clinical success due to severe toxicities. In particular, treatment with broad-spectrum MMP-inhibitors (MMPIs) caused musculoskeletal pain and inflammation. Selectivity may be essential for realizing the clinical potential of MMPIs. Here we review discoveries pinpointing membrane-bound MMPs as mediators of mechanisms underlying cancer and inflammation and as possible therapeutic targets for prevention/treatment of these diseases. We discuss strategies to target these therapeutic proteases using highly selective inhibitory agents (i.e., human blocking antibodies) against individual membrane-bound MMPs.
url http://dx.doi.org/10.1155/2011/191670
work_keys_str_mv AT laetitiadevy newstrategiesforthenextgenerationofmatrixmetalloproteinaseinhibitorsselectivelytargetingmembraneanchoredmmpswiththerapeuticantibodies
AT danieltdransfield newstrategiesforthenextgenerationofmatrixmetalloproteinaseinhibitorsselectivelytargetingmembraneanchoredmmpswiththerapeuticantibodies
_version_ 1725771163905294336

Similar Items